Arabic Arabic English English French French German German
dark

MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, announced positive topline results from its pivotal phase 3 pediatric clinical study with NexoBrid® to treat children with severe thermal burns, evaluating the efficacy and safety compared with standard-of-care. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

The environmental toll of disposable masks

Next Post

XPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio

Related Posts
Total
0
Share